Dyne Therapeutics is dedicated to improving the lives of individuals with genetically driven neuromuscular diseases by developing therapeutics targeting muscle and the central nervous system. The company advances clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also pursuing preclinical research for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Dyne's mission is to deliver functional improvement, making a significant impact on affected individuals, families, and communities.
Dyne Therapeutics is seeking a Director of CMC Management to lead project and portfolio management within their product development teams. The role will focus on ensuring seamless CMC plans for upcoming clinical programs, including the development of therapies for neuromuscular diseases such as Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy. The Director will partner with CMC teams to manage timelines, budgets, and ensure compliance with regulatory submissions.
Dyne Therapeutics is dedicated to improving the lives of individuals with genetically driven neuromuscular diseases by developing therapeutics targeting muscle and the central nervous system. The company advances clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also pursuing preclinical research for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Dyne's mission is to deliver functional improvement, making a significant impact on affected individuals, families, and communities.